Clinical trials: Diarrhea-predominant Irritable Bowel Syndrome
- Condition Diarrhea-predominant Irritable Bowel Syndrome
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Diarrhea-predominant Irritable Bowel Syndrome
Special Drug Use Surveillance of Irribow in Female Patients
The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.
- Trial name
- NCT02612649
- Testing
- Ramosetron
- Where
- 34 sites in Japan
- Volunteers
- 793 people
- Sponsor
- Astellas Pharma Inc